

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. - 14. (Cancelled)

15. (Currently amended) The diabody of claim 14, A diabody that recognizes CD22,  
wherein the diabody comprises the amino acid sequence of SEQ ID NO: 1.

16. (Currently amended) The diabody of claim 14, A diabody that recognizes CD22,  
wherein the diabody comprises the amino acid sequence of SEQ ID NO: 3.

17. - 18. (Cancelled)

19. (Currently amended) The diabody of claim 14, A diabody that recognizes CD22,  
wherein the diabody (a) comprises the amino acid sequences of complementarity determining  
regions (CDRs) 1-3 from SEQ ID NO:5 and the amino acid sequences of CDRs 1-3 from SEQ  
ID NO:7, and (b) induces apoptosis of a tumor cell expressing CD22.

20. (Currently amended) The diabody of claim 14, A diabody that recognizes CD22,  
wherein the diabody comprises (a) the amino acid sequences of CDRs 1-3 from SEQ ID  
NO:5[[,]] in which one or more 0-3 amino acids in each of the CDRs of SEQ ID NO:5 are  
substituted with another amino acid, inserted, deleted, and/or added; and (b) the amino acid  
sequences of CDRs 1-3 from SEQ ID NO:7[[,]] in which one or more 0-3 amino acids in each of  
the CDRs of SEQ ID NO:7 are substituted with another amino acid, inserted, deleted, and/or  
added; and wherein the diabody induces apoptosis of a tumor cell expressing CD22.

21. (Currently amended) The diabody of claim 14, A diabody that recognizes CD22, wherein the diabody (a) comprises the amino acid sequences of CDRs 1-3 from SEQ ID NO:9 and the amino acid sequences from CDRs 1-3 in SEQ ID NO:11, and (b) induces apoptosis of a tumor cell expressing CD22.

22. (Currently amended) The diabody of claim 14, A diabody that recognizes CD22, wherein the diabody comprises (a) the amino acid sequences of CDRs 1-3 from SEQ ID NO:9[[,]] in which one or more 0-3 amino acids in each of the CDRs of SEQ ID NO:9 are substituted with another amino acid, inserted, deleted, and/or added; and (b) the amino acid sequences of CDRs 1-3 from SEQ ID NO:11[[,]] in which one or more 0-3 amino acids in each of the CDRs of SEQ ID NO:11 are substituted with another amino acid, inserted, deleted, and/or added; and wherein the diabody induces apoptosis of a tumor cell expressing CD22.

23. - 27. (Cancelled)

28. (Previously presented) The diabody of claim 19, wherein the diabody is humanized.

29. (Previously presented) The diabody of claim 20, wherein the diabody is humanized.

30. (Previously presented) The diabody of claim 21, wherein the diabody is humanized.

31. (Previously presented) The diabody of claim 22, wherein the diabody is humanized.

32.-35. (Cancelled)

36. (Withdrawn) A method of inducing apoptosis of a cell, the method comprising contacting the cell with the diabody of claim 15.

37. (Withdrawn) The method of claim 36, wherein the cell is a tumor cell.

38. (Withdrawn) A method of inducing apoptosis of a cell, the method comprising contacting the cell with the diabody of claim 16.

39. (Withdrawn) The method of claim 38, wherein the cell is a tumor cell.

40. – 43. (Cancelled)

44. (Withdrawn) A method of inducing apoptosis of a cell, the method comprising contacting the cell with the diabody of claim 19.

45. (Withdrawn) The method of claim 44, wherein the cell is a tumor cell.

46. (Withdrawn) The method of claim 44, wherein the contacting takes place in a patient.

47. (Withdrawn) The method of claim 44, wherein the diabody is humanized.

48. (Withdrawn) A method of inducing apoptosis of a cell, the method comprising contacting the cell with the diabody of claim 20.

49. (Withdrawn) The method of claim 48, wherein the cell is a tumor cell.

50. (Withdrawn) The method of claim 48, wherein the contacting takes place in a patient.

51. (Withdrawn) The method of claim 48, wherein the diabody is humanized.

52. (Withdrawn) A method of inducing apoptosis of a cell, the method comprising contacting the cell with the diabody of claim 21.

53. (Withdrawn) The method of claim 52, wherein the cell is a tumor cell.

54. (Withdrawn) The method of claim 52, wherein the contacting takes place in a patient.

55. (Withdrawn) The method of claim 52, wherein the diabody is humanized.

56. (Withdrawn) A method of inducing apoptosis of a cell, the method comprising contacting the cell with the diabody of claim 22.

57. (Withdrawn) The method of claim 56, wherein the cell is a tumor cell.

58. (Withdrawn) The method of claim 56, wherein the contacting takes place in a patient.

59. (Withdrawn) The method of claim 56, wherein the diabody is humanized.

60. (New) The diabody of claim 20, wherein each of the substituted amino acids is a conservative amino acid substitution.

61. (New) The diabody of claim 20, wherein no more than one amino acid is substituted in each CDR.

62. (New) The diabody of claim 61, wherein each substituted amino acid is a conservative amino acid substitution.

63. (New) The diabody of claim 22, wherein each of the substituted amino acids is a conservative amino acid substitution.

64. (New) The diabody of claim 22, wherein no more than one amino acid is substituted in each CDR.

65. (New) The diabody of claim 64, wherein each substituted amino acid is a conservative amino acid substitution.

66. (New) The diabody of claim 15, wherein the diabody induces lymphoma or leukemia cell apoptosis.

67. (New) The diabody of claim 15, wherein the diabody is a dimer of two scFv, held together by non-covalent bonds.

68. (New) The diabody of claim 15, wherein the diabody is a single chain diabody.

69. (New) The diabody of claim 16, wherein the diabody induces lymphoma or leukemia cell apoptosis.

70. (New) The diabody of claim 16, wherein the diabody is a dimer of two scFv, held together by non-covalent bonds.

71. (New) The diabody of claim 16, wherein the diabody is a single chain diabody.

72. (New) The diabody of claim 19, wherein the diabody induces lymphoma or leukemia cell apoptosis.

73. (New) The diabody of claim 19, wherein the diabody is a dimer of two scFv, held together by non-covalent bonds.

74. (New) The diabody of claim 19, wherein the diabody is a single chain diabody.

75. (New) The diabody of claim 20, wherein the diabody induces lymphoma or leukemia cell apoptosis.

76. (New) The diabody of claim 20, wherein the diabody is a dimer of two scFv, held together by non-covalent bonds.

77. (New) The diabody of claim 20, wherein the diabody is a single chain diabody.

78. (New) The diabody of claim 21, wherein the diabody induces lymphoma or leukemia cell apoptosis.

79. (New) The diabody of claim 21, wherein the diabody is a dimer of two scFv, held together by non-covalent bonds.

80. (New) The diabody of claim 21, wherein the diabody is a single chain diabody.

81. (New) The diabody of claim 22, wherein the diabody induces lymphoma or leukemia cell apoptosis.

82. (New) The diabody of claim 22, wherein the diabody is a dimer of two scFv, held together by non-covalent bonds.

83. (New) The diabody of claim 22, wherein the diabody is a single chain diabody.